346 related articles for article (PubMed ID: 29690784)
21. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
22. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
[TBL] [Abstract][Full Text] [Related]
24. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
Chang S; Hanauer S
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
[TBL] [Abstract][Full Text] [Related]
25. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
26. Talking to patients about biosimilars.
Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M
Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243
[TBL] [Abstract][Full Text] [Related]
27. The US approach to biosimilars: the long-awaited FDA approval pathway.
Calvo B; Zuñiga L
BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
[TBL] [Abstract][Full Text] [Related]
28. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
29. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H
Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
31. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching.
Declerck P; Bakalos G; Zintzaras E; Barton B; Schreitmüller T
Clin Ther; 2018 May; 40(5):798-809.e2. PubMed ID: 29699853
[TBL] [Abstract][Full Text] [Related]
33. Molecular "Sameness" Is the Key Guiding Principle for Extrapolation to Multiple Indications.
McCamish M; Woollett GR
Clin Pharmacol Ther; 2017 May; 101(5):603-605. PubMed ID: 28074488
[TBL] [Abstract][Full Text] [Related]
34. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
35. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
[TBL] [Abstract][Full Text] [Related]
36. Are Biosimilars the Future of Oncology and Haematology?
Zinzani PL; Dreyling M; Gradishar W; Andre M; Esteva FJ; Boulos S; González Barca E; Curigliano G
Drugs; 2019 Oct; 79(15):1609-1624. PubMed ID: 31541401
[TBL] [Abstract][Full Text] [Related]
37. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
38. [Biosimilars in oncology: a therapeutic alternative to the reference products?].
Ludwig WD; Dicheva S
Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912
[TBL] [Abstract][Full Text] [Related]
39. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
40. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
